TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

A Drug's Impact on Global Symptoms and Its Effect on Positive Symptoms Are the Attributes that Most Influence Surveyed Psychiatrists' Prescribing Decisions in Schizophrenia, According to a New Report ...

August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...

Janssen announced positive results of its PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial that compared schizophrenia medications. Results showed that once-monthly Invega ...

Johnson & Johnson wrapped a Phase III study of a 3-month formulation of Invega Sustenna early after an independent monitoring group called it on positive efficacy ...

Johnson & JohnsonJNJ suffered a setback when the FDA issued a complete response letter (CRL) in response to the company's supplemental new drug application (sNDA) for the once-monthly long-acting ...

Janssen announced that the Food and Drug Administration (FDA) has approved the supplemental New Drug Applications (sNDAs) for Invega Sustenna (paliperidone palmitate) as either monotherapy or ...